companydata.dkNordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond: Financial statements 2023
CVR: 30197372
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond (CVR 30197372) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 7,068,563 and a net result of DKK 1,086,129 compared with DKK 466,886 the year before. That is a decrease of 4.7% compared with the year before. Equity amounted to DKK 3,832,364. The solvency ratio was 13.6%. The company had 12 employees in the financial year.
- Gross Profit
- 7,068,563 kr.
- Profit/Loss
- 1,086,129 kr.
- Equity
- 3,832,364 kr.
- Total Assets
- 28,263,951 kr.
- Employees
- 12
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 7.1 mio. | 1.1 mio. | 3.8 mio. | 12 |
| 2022 | - | 7.4 mio. | 467 t. | 2.7 mio. | 12 |
| 2021 | - | 4.6 mio. | -631 t. | 2.3 mio. | 10 |
| 2020 | - | 4.5 mio. | -238 t. | 2.9 mio. | 10 |
| 2019 | - | 5.8 mio. | 1.3 mio. | 3.1 mio. | 10 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2022. Gross profit came to DKK 7,416,455, and the net result was DKK 466,886.
About Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond is a Danish company of the type Erhvervsdrivende fond based in København Ø, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristine Madsen. The company has 2 employees. In 2025, the company reported a gross profit of DKK 7,463,032 and a net result of DKK -334,181 compared with DKK 1,408,745 the year before. Equity amounted to DKK 4,906,927.